{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"7"}]}],"title":"Participants With All-Causality TEAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"}]}],"title":"Participants With All-Causality SAEs"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"description":"An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs are events between first dose of study drug and up to discharge from study that are absent before treatment or that worsen relative to pretreatment state. An SAE is any untoward medical occurrence at any dose that: results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or results in congenital anomaly/birth defect.","groups":[{"description":"Participants received placebo during the 6-week double-blind phase (Part A) Q3W SC.","id":"OG000","title":"Placebo"},{"description":"Participants received PF-06946860 200 mg during the 6-week double-blind phase (Part A) Q3W SC.","id":"OG001","title":"PF-06946860 200mg Q3W"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The analysis population included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention.","reportingStatus":"POSTED","timeFrame":"Day 1 through Week 6 (for a period of 6 weeks)","title":"Number of Participants With All-Causality Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) in Part A","type":"SECONDARY","unitOfMeasure":"Participants"}